Trial
NCT06572631
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Acute Myeloid Leukemia
Intervention
Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001
Why stopped
cprmc withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-25